Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC
Shots:
- The US FDA has cleared an IND application to initiate P-Ib/II (SHIELD-2) to evaluate the safety, tolerability & preliminary efficacy of elzovantinib (MET inhibitor) + EQRx’s aumolertinib in patients with EGFR mutant MET-amplified NSCLC. The trial is expected to initiate in mid-2022
- In preclinical data, the combination therapy has the potential to increase anti-tumor activity based on complementary mechanisms while 15 to 20% has developed MET amplification who progress on a 1L EGFR inhibitor develop MET amplification based on acquired resistance
- Aumolertinib is an EGFR inhibitor & was approved in China for 1L treatment of EGFR mutant NSCLC & 2L treatment of T790M+ EGFR mutant NSCLC
Ref: Globe Newswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com